The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLong Ideas - Pfizer (NYSE:PFE) announced this morning that the FDA delayed a decision on its rheumatoid arthritis treatment Tofacitinib by at least three months. The agency was … Continue Reading
Read nowLong Ideas - Medtronic (NYSE:MDT) reported fiscal 1Q 2013 EPS of $0.85, in-line with expectations, with revenues also largely meeting forecasts ($4.01 billion vs. consensus estimate of $4.0 … Continue Reading
Read nowQuick Picks - Shares of Amarin Corp. (NASDAQ:AMRN) are up about 2% this morning against a weak tape, as Jeffries analyst Thomas Wei commented that the delay in … Continue Reading
Read nowLong Ideas - Hyperion Therapeutics (NASDAQ:HPTX) received two Buy ratings this morning after going public in late July. Both Cowen and Needham initiated coverage on HPTX, with Needham … Continue Reading
Read now- StemCells, Inc. (NASDAQ:STEM) is down 9% this morning after a downgrade from Roth Capital lowered STEM’s price target from $5.00 to $1.80; a “Buy” rating … Continue Reading
Read now- Investors will have to wait a few more weeks to find out whether Amarin’s (NASDAQ:AMRN) recently approved Vascepa high-triglyceride treatment will receive New Chemical Entity … Continue Reading
Read now- Developer of the recently-approved Qsymia weight-loss drug, Vivus, (NASDAQ:VVUS) is down 7% this morning after a downgrade from Jefferies; the analyst gave Vivus a new … Continue Reading
Read now
